EUVIMEDAtrasti EUVIMED
Multizentrische StudieOpen access

Congenital Cytomegalovirus Testing Outcomes From the ValEAR Trial

Quinn T Orb iD, Megan Pesch, Chelsea M Allen, Ashlea Wilkes, Iram Ahmad, Kristan Alfonso, Stephanie Moody Antonio, Leena Bhattacharya Mithal, Jennifer V Brinkmeier, Daniela Carvalho, Dylan Chan, Alan G Cheng and 24 more

Otolaryngology–Head and Neck Surgery · 2024

DOI: 10.1002/ohn.670 ↗

At a glance

Multizentrische Studie in Otolaryngology–Head and Neck Surgery, 2024. Written by Quinn T Orb and 35 co-authors. Institution: Division of Otolaryngology-Head and Neck Surgery, University of Utah School of Medicine, Salt Lake City, Utah, USA. Major MEDLINE topics: Cytomegalovirus Infections, Neonatal Screening. Cited 20 times so far (Crossref); 85 references. The full text is freely available in PubMed Central. Funded by: NCRR NIH HHS, NCATS NIH HHS, NICHD NIH HHS.

SantraukaSubjectsBibliografiniai duomenysCiteRelated studies

Abstract (original language)

Objective

To determine the positivity rate of congenital cytomegalovirus (cCMV) testing among universal, hearing‐targeted CMV testing (HT‐cCMV) and delayed targeted dried blood spot (DBS) testing newborn screening programs, and to examine the characteristics of successful HT‐cCMV testing programs. Study Design Prospective survey of birth hospitals performing early CMV testing.

Setting

Multiple institutions.

Methods

Birth hospitals participating in the National Institutes of Health ValEAR clinical trial were surveyed to determine the rates of cCMV positivity associated with 3 different testing approaches: universal testing, HT‐cCMV, and DBS testing. A mixed methods model was created to determine associations between successful HT‐cCMV screening and specific screening protocols.

Results

Eighty‐two birth hospitals were surveyed from February 2019 to December 2021. Seven thousand six hundred seventy infants underwent universal screening, 9017 infants HT‐cCMV and 535 infants delayed DBS testing. The rates of cCMV positivity were 0.5%, 1.5%, and 7.3%, respectively. The positivity rate for universal CMV screening was less during the COVID‐19 pandemic than that reported prior to the pandemic. There were no statistically significant drops in positivity for any approach during the pandemic. For HT‐cCMV testing, unique order sets and rigorous posttesting protocols were associated with successful screening programs.

Conclusion

Rates of cCMV positivity differed among the 3 approaches. The rates are comparable to cohort studies reported in the literature. Universal CMV prevalence decreased during the pandemic but not significantly. Institutions with specific order set for CMV testing where the primary care physician orders the test and the nurse facilitates the testing process exhibited higher rates of HT‐cCMV testing.

Subjects

MeSH terms (MEDLINE)

Cytomegalovirus InfectionsNeonatal ScreeningHumansInfant, NewbornProspective StudiesCOVID-19United StatesDried Blood Spot TestingFemaleMale

Author keywords

congenital cytomegalovirusdried blood spot testinghearing‐targeted cytomegalovirus testingpediatric hearing lossuniversal cytomegalovirus testing

Authors and institutions

  • Division of Otolaryngology-Head and Neck Surgery, University of Utah School of Medicine, Salt Lake City, Utah, USA.
  • ValEAR Study Group, Worcester, Massachusetts, USA.
  • Department of Population Health Sciences, Division of Biostatistics, University of Utah School of Medicine, Salt Lake City, Utah, USA.

ORCID profiles: Quinn T Orb

Funding

  • NCRR NIH HHS
  • NCATS NIH HHS
  • NICHD NIH HHS
  • NIDCD NIH HHS

Cite

APA

Orb, Q. T., Pesch, M., Allen, C. M., Wilkes, A., Ahmad, I., Alfonso, K., Antonio, S. M., Mithal, L. B., Brinkmeier, J. V., Carvalho, D., Chan, D., Cheng, A. G., Chi, D., Cohen, M., Discolo, C. M., Duran, C., Germiller, J., Gibson, L., Grunstein, E., …, & Park, A. H. (2024). Congenital Cytomegalovirus Testing Outcomes From the ValEAR Trial. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.670

Vancouver

Orb QT, Pesch M, Allen CM, Wilkes A, Ahmad I, Alfonso K, et al. Congenital Cytomegalovirus Testing Outcomes From the ValEAR Trial. Otolaryngology–Head and Neck Surgery. 2024. doi:10.1002/ohn.670

BibTeX
@article{Orb2024,
  author = {Orb, Quinn T and Pesch, Megan and Allen, Chelsea M and Wilkes, Ashlea and Ahmad, Iram and Alfonso, Kristan and Antonio, Stephanie Moody and Mithal, Leena Bhattacharya and Brinkmeier, Jennifer V and Carvalho, Daniela and Chan, Dylan and Cheng, Alan G and Chi, David and Cohen, Michael and Discolo, Christopher Michael and Duran, Carlos and Germiller, John and Gibson, Laura and Grunstein, Eli and Harrison, Gail and Lee, Kenneth and Hawley, Karen and Kohlhoff, Stephan and Melvin, Ann and MacArthur, Carol and Nassar, Michel and Neff, Laura and Pecha, Phayvanh and Salvatore, Christine and Schoem, Scott and Virgin, Frank and Saunders, James and Schleiss, Mark and Smith, Richard J H and Sood, Sunil and Park, Albert H},
  title = {Congenital Cytomegalovirus Testing Outcomes From the ValEAR Trial},
  journal = {Otolaryngology–Head and Neck Surgery},
  year = {2024},
  doi = {10.1002/ohn.670}
}
Start for free →